Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on March 16, 2012, reporting an event that occurred on March 13, 2012. The company is incorporated in Nevada and is based in Englewood Cliffs, NJ.
Key Financial Metrics
The filing reports the issuance of a senior convertible promissory note with the following terms:
- Principal Amount: $1,000,000
- Interest Rate: 10% per annum
- Conversion Price: $1.50 per share of common stock
- Security: First priority security interest in "Vendor Proceeds" (proceeds from sales to a certain vendor)
- Repayment Trigger: Payable upon the Final Maturity Date, consummation of a financing with net proceeds equal to or greater than 1.5 times the remaining principal, or an Event of Default.
The filing does not provide data on revenue, operating profit, cash flow, margins, or total liquidity beyond the specific note transaction.
Material Changes
The primary material change is the increase in debt obligations and potential equity dilution resulting from the sale of the $1,000,000 note. Additionally, certain existing holders of senior secured indebtedness agreed to subordinate their security interest in the Vendor Proceeds to the new investor.
Guidance, Risks, and Unusual Items
Conversion Limitation: The note is subject to a beneficial ownership limitation; the investor cannot convert the note if it would result in them owning more than 4.99% of the company's outstanding common stock (subject to waiver).
Regulatory Status: The securities were sold to an accredited investor under Section 4(2) and Regulation D (Rule 506) exemptions, meaning they were unregistered.
Risks: Repayment is contingent on specific financing events or vendor proceeds, introducing uncertainty regarding the timing of principal repayment.
Investor Verification Checklist
- Verify the identity of the "Vendor" and the status of "Vendor Proceeds" to assess repayment likelihood.
- Confirm the total outstanding senior secured indebtedness to understand the full capital structure.
- Review the "Event of Default" definitions in the attached Exhibit 10.1 (Form of Note).
- Check for any waivers regarding the 4.99% beneficial ownership cap.
- Clarify the discrepancy between the requested company name (Cocrystal Pharma) and the filing registrant (BioZone Pharmaceuticals).